BioSpace News Archive

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Xofluza® for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

SURE Retractors Inc., a medical device company that has developed a range of industry-disruptive retractors for spinal surgery, announced that Max Reinhardt has been elected to the company’s board of directors, effective immediately.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a MedTech company commercializing IzoView, an advanced three-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer, is pleased to report the Company has successfully relocated IzoView and associated components and completed the transition of all major medical device engineering and product development operations to California.

Interaxon Inc. ( Muse®), the leading consumer neurotechnology company, announced that it has closed an oversubscribed $9.5M USD Series C funding round through a non-brokered private placement.

On August 4th, monkeypox (MPV) was declared a national health emergency after reported cases in the US rose in one month by approximately 900%.

Scanslated, Inc., a radiologist-led healthcare technology company, today announced that it has partnered with Duke Health to deliver its patient-centered, interactive radiology reporting service to patients at Duke’s three hospitals and 14 outpatient imaging locations servicing nearly two million patients per year.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following.

Medicenna Therapeutics Corp. is pleased to announce the closing of its previously announced marketed underwritten public offering of units of the Company in Canada and in the United States at a price to the public of US$1.50 per Unit, for aggregate gross proceeds to the Company of approximately US$20 million, before deducting underwriting commissions and Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants.

Intend™, a patient-centric healthcare management software provider, today announced support for Monkeypox Vaccinations on the Intend platform.